CUE vs. QTTB, NBTX, AVIR, KMDA, XOMA, ADCT, CRMD, MRSN, VNDA, and NATR
Should you be buying Cue Biopharma stock or one of its competitors? The main competitors of Cue Biopharma include Q32 Bio (QTTB), Nanobiotix (NBTX), Atea Pharmaceuticals (AVIR), Kamada (KMDA), XOMA (XOMA), ADC Therapeutics (ADCT), CorMedix (CRMD), Mersana Therapeutics (MRSN), Vanda Pharmaceuticals (VNDA), and Nature's Sunshine Products (NATR). These companies are all part of the "pharmaceutical preparations" industry.
Q32 Bio (NASDAQ:QTTB) and Cue Biopharma (NASDAQ:CUE) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, media sentiment, earnings, community ranking, institutional ownership, risk, profitability and valuation.
In the previous week, Cue Biopharma had 2 more articles in the media than Q32 Bio. MarketBeat recorded 3 mentions for Cue Biopharma and 1 mentions for Q32 Bio. Cue Biopharma's average media sentiment score of 1.68 beat Q32 Bio's score of 1.43 indicating that Q32 Bio is being referred to more favorably in the media.
Q32 Bio has a beta of -0.26, meaning that its stock price is 126% less volatile than the S&P 500. Comparatively, Cue Biopharma has a beta of 1.98, meaning that its stock price is 98% more volatile than the S&P 500.
Cue Biopharma received 139 more outperform votes than Q32 Bio when rated by MarketBeat users. However, 100.00% of users gave Q32 Bio an outperform vote while only 51.81% of users gave Cue Biopharma an outperform vote.
Cue Biopharma has higher revenue and earnings than Q32 Bio. Cue Biopharma is trading at a lower price-to-earnings ratio than Q32 Bio, indicating that it is currently the more affordable of the two stocks.
31.3% of Q32 Bio shares are owned by institutional investors. Comparatively, 35.0% of Cue Biopharma shares are owned by institutional investors. 16.1% of Q32 Bio shares are owned by insiders. Comparatively, 7.5% of Cue Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Q32 Bio currently has a consensus price target of $49.67, indicating a potential upside of 94.77%. Cue Biopharma has a consensus price target of $8.00, indicating a potential upside of 390.80%. Given Q32 Bio's higher probable upside, analysts plainly believe Cue Biopharma is more favorable than Q32 Bio.
Q32 Bio has a net margin of 0.00% compared to Q32 Bio's net margin of -711.84%. Cue Biopharma's return on equity of -117.63% beat Q32 Bio's return on equity.
Summary
Cue Biopharma beats Q32 Bio on 10 of the 19 factors compared between the two stocks.
Get Cue Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for CUE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CUE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cue Biopharma Competitors List
Related Companies and Tools
